Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment

Ali Zirakzadeh, Robin Patel

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Vancomycin-resistant enterococci (VRE) are becoming a major concern in medical practice. Their increased prevalence and their ability to transfer vancomycin resistance to other bacteria (including methicillin-resistant Staphylococcus aureus) have made them a subject of close scrutiny and intense investigation. Colonization is usually acquired by susceptible hosts in an environment with a high rate of patient colonization with VRE (eg, intensive care units, oncology units). Vancomycin-resistant enterococci can survive in the environment for prolonged periods (>1 week), can contaminate almost any surface, and can be passed from one patient to another by health care workers. Whether VRE colonization leads to infection depends on the health status of the patient. Whereas immunocompetent patients colonized with VRE are at low risk for infection, weakened hosts (patients with hematologic disorders, transplant recipients, or severely ill patients) have an increased likelihood of developing infection following colonization. Quinupristin-dalfopristin and linezolid are among the anti-infective agents that have recently become available to treat infection caused by VRE. Other antimicrobials are currently under development. Molecular techniques such as polymerase chain reaction and standard culture studies are being used to detect VRE colonization, infection, and outbreaks.

Original languageEnglish (US)
Pages (from-to)529-536
Number of pages8
JournalMayo Clinic Proceedings
Volume81
Issue number4
DOIs
StatePublished - 2006

Fingerprint

Infection
Linezolid
Therapeutics
Vancomycin Resistance
Methicillin-Resistant Staphylococcus aureus
Anti-Infective Agents
Vancomycin-Resistant Enterococci
Health Status
Disease Outbreaks
Intensive Care Units
Bacteria
Delivery of Health Care
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vancomycin-resistant enterococci : Colonization, infection, detection, and treatment. / Zirakzadeh, Ali; Patel, Robin.

In: Mayo Clinic Proceedings, Vol. 81, No. 4, 2006, p. 529-536.

Research output: Contribution to journalArticle

@article{b6618fdcd9b447f6a71291a1364702fc,
title = "Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment",
abstract = "Vancomycin-resistant enterococci (VRE) are becoming a major concern in medical practice. Their increased prevalence and their ability to transfer vancomycin resistance to other bacteria (including methicillin-resistant Staphylococcus aureus) have made them a subject of close scrutiny and intense investigation. Colonization is usually acquired by susceptible hosts in an environment with a high rate of patient colonization with VRE (eg, intensive care units, oncology units). Vancomycin-resistant enterococci can survive in the environment for prolonged periods (>1 week), can contaminate almost any surface, and can be passed from one patient to another by health care workers. Whether VRE colonization leads to infection depends on the health status of the patient. Whereas immunocompetent patients colonized with VRE are at low risk for infection, weakened hosts (patients with hematologic disorders, transplant recipients, or severely ill patients) have an increased likelihood of developing infection following colonization. Quinupristin-dalfopristin and linezolid are among the anti-infective agents that have recently become available to treat infection caused by VRE. Other antimicrobials are currently under development. Molecular techniques such as polymerase chain reaction and standard culture studies are being used to detect VRE colonization, infection, and outbreaks.",
author = "Ali Zirakzadeh and Robin Patel",
year = "2006",
doi = "10.4065/81.4.529",
language = "English (US)",
volume = "81",
pages = "529--536",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Vancomycin-resistant enterococci

T2 - Colonization, infection, detection, and treatment

AU - Zirakzadeh, Ali

AU - Patel, Robin

PY - 2006

Y1 - 2006

N2 - Vancomycin-resistant enterococci (VRE) are becoming a major concern in medical practice. Their increased prevalence and their ability to transfer vancomycin resistance to other bacteria (including methicillin-resistant Staphylococcus aureus) have made them a subject of close scrutiny and intense investigation. Colonization is usually acquired by susceptible hosts in an environment with a high rate of patient colonization with VRE (eg, intensive care units, oncology units). Vancomycin-resistant enterococci can survive in the environment for prolonged periods (>1 week), can contaminate almost any surface, and can be passed from one patient to another by health care workers. Whether VRE colonization leads to infection depends on the health status of the patient. Whereas immunocompetent patients colonized with VRE are at low risk for infection, weakened hosts (patients with hematologic disorders, transplant recipients, or severely ill patients) have an increased likelihood of developing infection following colonization. Quinupristin-dalfopristin and linezolid are among the anti-infective agents that have recently become available to treat infection caused by VRE. Other antimicrobials are currently under development. Molecular techniques such as polymerase chain reaction and standard culture studies are being used to detect VRE colonization, infection, and outbreaks.

AB - Vancomycin-resistant enterococci (VRE) are becoming a major concern in medical practice. Their increased prevalence and their ability to transfer vancomycin resistance to other bacteria (including methicillin-resistant Staphylococcus aureus) have made them a subject of close scrutiny and intense investigation. Colonization is usually acquired by susceptible hosts in an environment with a high rate of patient colonization with VRE (eg, intensive care units, oncology units). Vancomycin-resistant enterococci can survive in the environment for prolonged periods (>1 week), can contaminate almost any surface, and can be passed from one patient to another by health care workers. Whether VRE colonization leads to infection depends on the health status of the patient. Whereas immunocompetent patients colonized with VRE are at low risk for infection, weakened hosts (patients with hematologic disorders, transplant recipients, or severely ill patients) have an increased likelihood of developing infection following colonization. Quinupristin-dalfopristin and linezolid are among the anti-infective agents that have recently become available to treat infection caused by VRE. Other antimicrobials are currently under development. Molecular techniques such as polymerase chain reaction and standard culture studies are being used to detect VRE colonization, infection, and outbreaks.

UR - http://www.scopus.com/inward/record.url?scp=33645674134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645674134&partnerID=8YFLogxK

U2 - 10.4065/81.4.529

DO - 10.4065/81.4.529

M3 - Article

C2 - 16610573

AN - SCOPUS:33645674134

VL - 81

SP - 529

EP - 536

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -